Shots:
- China’s NMPA has accepted NDA of fruquintinib + sintilimab for the treatment of pts with locally advanced or metastatic renal cell carcinoma who have progressed on one tyrosine kinase inhibitor therapy
- NDA is backed by the P-II/III (FRUSICA-2) trial assessing fruquintinib + sintilimab vs axitinib/everolimus monotx. for 2L treatment of renal cell carcinoma pts
- Trial met its 1EP of improved PFS per BICR, with improvements observed across 2EPs of ORR & DoR; data to be presented at a future conference
Ref: PRNewswire | Image: HUTCHMED| Press Release
Related News:- HUTCHMED Reports Enrollment Completion in P-II Trial of Savolitinib for Gastric Cancer in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
